News | May 29, 2007

Web Conference Covers Cardiac Safety in Drug Development

May 30, 2007 -- Xtalks and eResearchTechnology will present a Web conference titled, "Best Practices in Cardiac Safety Data Collection Before and After the Thorough QT Trial," on June 7, 10 a.m. to noon, EDT.

Focus on cardiac safety in new drug development has increased dramatically in recent years. ICH E14 guidance was finalized in May 2005, and an important component of the guidance is the requirement of the Thorough QT Trial (TQT) in the development of new drug candidates.

Dr. Jeffrey Litwin will provide current insights into the differences between Phase I versus Phases II-III and Phase IV cardiac safety testing. He will address common ECG collection practices at sites versus best practices and when one approach may be preferred over another. Dr. Litwin will address the impact of the TQT on Phase III programs and provide additional discussion on ECG data considerations beyond QTc. Dr. Litwin will address how implementation of best practices ensures data quality and consistency and reduces data evaluation time.

The Web cast will address:
-- What is the difference between cardiac safety assessments in Phase I versus Phase II-III and Phase IV?

-- When and how many ECGs should be acquired and how should ECG measurements and interpretations be conducted?

-- How should ECGs be acquired at clinical sites and what is the role of local interpretation of ECG data?

-- How should ECG data be analyzed?

To register for the free conference visit http://www.xtalks.com/csdata.ashx, or for more information visit www.xtalks.com

Related Content

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Overlay Init